- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01586468
PILOT STUDY OF THE EFFICACY AND SAFETY OF WF10 IN SUBJECTS SUFFERING FROM PERSISTENT ALLERGIC RHINITIS
A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF THE EFFICACY AND SAFETY OF WF10 IN SUBJECTS SUFFERING FROM PERSISTENT ALLERGIC RHINITIS
Objectives To assess the efficacy and safety of WF10 infusions in the treatment of subjects with persistent allergic rhinitis.
Study Design Randomized, double-blind, placebo-controlled, parallel-group, single-centre trial.
Subjects 50 subjects (25 per treatment group) with history of persistent allergic rhinitis for at least 2 years prior to enrolment and a positive allergen skin test. Subjects will be required to have a minimum mean score ≥6 for the baseline Total Nasal Symptom Score (TNSS) (mean score of morning and evening reflective TNSS assessments for the 3 days prior to randomization and treatment.
Treatments At the first treatment visit (T1), subjects that comply with the inclusion and exclusion criteria will be randomized into one of two treatment groups: WF10, or placebo.
Each individual treatment dose of study drug solution is 0.5 mL/kg body weight, diluted into 500 mL saline solution. Treatment will be administered once daily for 5 consecutive days (Visits T1-T5) via intravenous infusion.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04109
- POIS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of persistent allergic rhinitis for at least 2 years prior to enrolment. Concurrent history of asthma is permitted.
- Positive allergen skin test to the relevant allergen(s), performed within the previous 2 years prior to enrolment.
- Mean score ≥6 for the baseline Total Nasal Symptom Score (TNSS)
- Screening laboratory values within normal range, except those related to the primary disease, including eosinophil count, and elevated glucose is allowed.
- Age between 18 and 70 years, inclusive.
- The subject must be able to read and understand German well enough to answer the questions in the TNSS and Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ), without any translation or explanation.
If female, the subject:
Cannot become pregnant because she is surgically sterile (hysterectomy or tubal ligation), or is postmenopausal for at least 6 months prior to the screening visit.
OR
- Is not pregnant, with a negative pregnancy test at screening (confirmed at the baseline visit), and uses an acceptable method of contraception with a low failure rate (PEARL Index) (i.e. less than 1% per year) when used consistently and correct (including oral contraceptives, hormone implant, intrauterine device, , male sexual partner(s) surgically sterile, abstinence).
- Except for persistent allergic rhinitis, the subject is in reasonably good health, as determined by the discretion of the study investigator (based on the physical examination and electrocardiogram [ECG] results).
- The subject has signed an informed consent form.
Exclusion Criteria:
- Non-allergic rhinitis, rhinitis medicamentosa, idiopathic rhinitis or sinusitis.
- History of nasal surgery in the 6 months prior to enrolment.
- An upper respiratory or sinus infection within the 2 weeks prior to enrolment.
- Presence of a severely deviated septum, septal perforation, structural nasal defect or large nasal polyps causing obstruction.
- Use of intramuscular glucocorticosteroids in the 12 weeks prior to enrolment; use of oral, intravenous or medium or high daily dose inhaled glucocorticosteroids (as described in GINA guidelines - see App. III)) in the 4 weeks prior to enrolment; use of topical (nasal or ocular) glucocorticosteroids in the 2 weeks prior to enrolment. .
- Use of anti-IgE antibodies (e.g. omalizumab) in the 12 weeks prior to enrolment.
- Use of anti-leukotrienes (e.g. montelukast) in the 4 weeks prior to enrolment.
- Unwillingness to discontinue prohibited medications and avoid their use during the study (see section 10.1.5 for a complete list of prohibited medications).
- Severe haematopoetic, cardiovascular, hepatic, renal, neurological or psychiatric disease.
- Glucose-6-phosphate dehydrogenase deficiency (activity < 60% = < WHO class 4)
- A female subject who is lactating.
- Planned travel outside of the study area during the first 22 days of the study.
- Any infirmity, disability or geographical location that would limit compliance with the protocol.
- A subject who has previously been randomized into this study, received at least one dose of study treatment and been withdrawn from this trial will not be allowed to re-enter.
- Use of another investigational drug within the 30 days prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: NaCl Solution
|
NaCl Solution
|
Experimental: WF10 0.5 ml/kg BW
|
0.5 mg/kg B.W.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
TNSS
Time Frame: 9 weeks
|
9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MiniRQLQ score, POHA score, and rhinometric and spirometric parameters
Time Frame: 9 weeks
|
9 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christian Gessner, M.D., POIS
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WF10-07-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinitis
-
Universitaire Ziekenhuizen KU LeuvenAZ Sint-Jan AVRecruitingPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis | Local Allergic RhinitisBelgium
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
ALK-Abelló A/SCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Humanis Saglık Anonim SirketiCompletedPerennial Allergic Rhinitis | Seasonal Allergic RhinitisIndia
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
West Penn Allegheny Health SystemPennsylvania Allergy and Asthma Research FoundationCompletedAllergy | Perennial Allergic Rhinitis | Seasonal Allergic RhinitisUnited States
-
Ahn-Gook Pharmaceuticals Co.,LtdSamsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaboratorsCompletedAllergic Rhinitis | Perennial Allergic Rhinitis | Non-seasonal Allergic RhinitisKorea, Republic of
-
Glenmark Specialty S.A.CompletedSeasonal Allergic Rhinitis (SAR)United States
Clinical Trials on NaCl Solution
-
Stefania La Grutta, MDCompleted
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
University of EdinburghUnknownVirus Diseases | COVID | Upper Respiratory Tract Infections | Virus | Virus SheddingUnited Kingdom
-
Thomas Jefferson UniversityUnknownPancreaticoduodenectomyUnited States
-
Ankara City Hospital BilkentNot yet recruitingLabor Pain and to Reduce Pain
-
Heinrich-Heine University, DuesseldorfCSL BehringWithdrawnBlood Loss, SurgicalGermany
-
Chulalongkorn UniversityNational Research Council of ThailandTerminated
-
Polyheal Ltd.Unknown
-
Ostergotland County Council, SwedenLinkoeping UniversityCompleted